Last updated: 2026-10-03 04:09:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Merck & Co., Inc. (MRK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $144.31, with a market capitalisation of $358.50B and a P/E ratio of 111.82. Over the past 52 weeks, its price has ranged from $82.01 to $156.92. This page covers its latest market performance, valuation, price trends and company information.
$358.50B | |
$143.77 | |
$156.92 | |
$15.32 | |
$143.81 | |
5.45M | |
9.83M | |
111.82 | |
$156.92 | |
$82.01 | |
2.34% | |
-- |
Merck & Co., Inc. (MRK) last closed at $143.81 as of 2026-10-02 23:45:57, unchanged from the previous close of $143.81.
During the latest regular trading session, MRK traded between $15.32 and $156.92, with a volume of 5.45M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Merck & Co., Inc. (MRK) moved from $148.08 to $144.31, representing a decline of 2.55% ($3.77).
The stock traded between $142.75 and $152.01 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 8.90 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 83.2%
MRK is currently trading at $144.31, placing it 83.2% of the way from its 52-week low of $82.01 to its 52-week high of $156.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Merck & Co., Inc. (MRK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.